Outlook Therapeutics, Inc. (OTLK) — 10-K Filings
All 10-K filings from Outlook Therapeutics, Inc.. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
OTLK Launches LYTENAVA in Europe, Faces US FDA Hurdles for Wet AMD Drug
— Dec 19, 2025 Risk: high
Outlook Therapeutics, Inc. (OTLK) reported significant developments for its ophthalmic formulation of bevacizumab, ONS-5010/LYTENAVA, for wet age-related macula -
Outlook Therapeutics Files 2024 10-K
— Dec 27, 2024 Risk: medium
Outlook Therapeutics, Inc. filed its 10-K for the fiscal year ending September 30, 2024. The company, formerly known as Oncobiologics, Inc., is in the biologica
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX